STOCK TITAN

Capricor Therapeutics Inc - CAPR STOCK NEWS

Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.

Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.

Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.

Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.

Rhea-AI Summary

OmniAb (NASDAQ: OABI) has announced two strategic appointments to its Board of Directors: Philip J. Gotwals, Ph.D., and Steve Crouse, while Director Sarah Boyce steps down after nearly six years of service. These changes increase the board size to seven members.

Dr. Gotwals brings 30 years of biopharmaceutical experience, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research, where his team executed over 50 major strategic transactions. He will serve on the Human Capital Management & Compensation Committee and Science & Technology Committee.

Steve Crouse, currently Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, contributes over 20 years of life sciences expertise. He will serve on the Audit Committee and Science & Technology Committee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
management
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced its participation in the 2025 Piper Sandler Virtual Cardio Day on April 2, 2025. CEO Linda Marbán will lead a fireside chat from 12:00-12:30 p.m. ET to discuss updates on deramiocel, their lead program for treating Duchenne muscular dystrophy (DMD).

Deramiocel, an allogeneic cardiac-derived cell therapy, has demonstrated immunomodulatory and anti-fibrotic properties in preserving cardiac and skeletal muscle function in dystrophiopathies. The company is also developing its proprietary StealthX™ platform for exosome technology applications in vaccinology and targeted therapeutic delivery.

Capricor has secured an exclusive commercialization and distribution agreement with Nippon Shinyaku Co., for deramiocel in the United States and Japan, pending regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
conferences
-
Rhea-AI Summary

Capricor Therapeutics (CAPR) announced significant developments in Q4 2024 and FY2024. The FDA has accepted their Biologics License Application (BLA) for deramiocel, granting priority review with a PDUFA date of August 31, 2025. The therapy targets Duchenne muscular dystrophy (DMD) cardiomyopathy.

Key financial highlights include:

  • Cash position of $151.5M as of December 31, 2024
  • Q4 2024 revenues of $11.1M (vs $12.1M in Q4 2023)
  • FY2024 revenues of $22.3M (vs $25.2M in 2023)
  • Net loss of $7.1M in Q4 2024 ($0.16 per share)
  • Current cash expected to support operations into 2027

Clinical data from the HOPE-2 open label extension trial showed a 52% slowing of disease progression over 3 years. The company received a $10M milestone payment from Nippon Shinyaku and expanded its manufacturing capacity in San Diego.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.51%
Tags
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced positive long-term data from its HOPE-2 open label extension trial for deramiocel, showing significant efficacy in treating Duchenne muscular dystrophy (DMD). The data, presented at the 2025 MDA Conference, demonstrated a 52% slowdown in disease progression over three years.

Key findings show patients treated with deramiocel experienced an average decline of 3.46 points in Performance of the Upper Limb (PUL 2.0) total score, compared to 7.19 points in the control group (p=0.019). The treatment effect improved yearly, with mean annual PUL 2.0 declines of 1.8, 1.2, and 1.1 points in Years 1, 2, and 3 respectively.

The drug maintained a favorable safety profile with no new safety signals. The FDA has accepted Capricor's Biologics License Application for DMD-associated cardiomyopathy, with a PDUFA date set for August 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, has scheduled its fourth quarter and full year 2024 financial results announcement for March 19, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be made available on the company's website following the live broadcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences earnings
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) has received FDA acceptance for its Biologics License Application (BLA) for deramiocel, an investigational cell therapy targeting Duchenne muscular dystrophy (DMD) cardiomyopathy. The FDA has granted Priority Review with a PDUFA target action date of August 31, 2025.

NS Pharma, a subsidiary of Nippon Shinyaku, will be exclusively responsible for the U.S. commercialization and distribution of deramiocel, following their exclusive distribution agreement established in January 2022. The FDA has not identified any potential review issues at this time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR), a biotech company focused on developing cell and exosome-based therapeutics for rare diseases, has announced its participation in Leerink's Global Healthcare Conference 2025. The conference will take place from March 10-12, 2025, in Miami, Florida.

The company's management will engage in one-on-one investor meetings and deliver a corporate presentation on Wednesday, March 12, 2025, from 1:00-1:40 p.m. ET. During the presentation, Capricor will provide updates on their lead program deramiocel, which targets the treatment of Duchenne muscular dystrophy (DMD), along with other scientific and corporate developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
conferences
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced FDA acceptance and Priority Review of its Biologics License Application (BLA) for deramiocel, a cell therapy treatment for Duchenne muscular dystrophy (DMD) cardiomyopathy. The FDA set a PDUFA target action date of August 31, 2025.

If approved, deramiocel would be the first therapy specifically targeting DMD cardiomyopathy. The treatment would be administered quarterly as a lifelong therapy. The BLA submission is supported by data from Phase 2 HOPE-2 and HOPE-2 Open Label Extension trials, compared with FDA-funded natural history data.

The FDA has not identified any potential review issues and has not yet decided on the need for an Advisory Committee meeting. Deramiocel has received Orphan Drug Designation from both FDA and EMA, along with RMAT designation in the U.S. and ATMP Designation in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, has announced its participation in three major upcoming investor conferences. The company will be presenting at:

• The Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) on February 12, 2025, from 12:00-12:30 p.m. ET
• The Barclays 27th Annual Global Healthcare Conference in Miami, FL (March 11-13, 2025)
• The 37th Annual ROTH Conference in Dana Point, CA (March 16-18, 2025)

During these conferences, Capricor's management will provide updates on their lead program, deramiocel, for treating Duchenne muscular dystrophy (DMD), along with general scientific and corporate updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) has completed its Biologics License Application (BLA) submission to the FDA for deramiocel, seeking full approval for treating Duchenne muscular dystrophy (DMD) cardiomyopathy. The submission triggers a $10 million milestone payment from Nippon Shinyaku.

The BLA is supported by cardiac data from Phase 2 HOPE-2 and HOPE-2 Open Label Extension trials, compared with FDA-funded natural history data. Capricor has requested priority review, which could reduce the review timeline from 10 to 6 months.

Deramiocel has received Orphan Drug Designation from both FDA and EMA, RMAT Designation in the U.S., and ATMP Designation in Europe. If approved, it would be the first therapy for DMD cardiomyopathy, and Capricor would be eligible for a Priority Review Voucher based on its rare pediatric disease designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

CAPR Stock Data

440.33M
38.00M
16.84%
38.26%
17.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEVERLY HILLS